Talquetamab–daratumumab in relapsed or refractory myeloma (Registro nro. 22827)
[ vista simple ]
| 000 -Cabecera | |
|---|---|
| Campo de control interno | 03287nam a2200325 4500 |
| 001 - Número de control | |
| control field | ESSALUD |
| 005 - Fecha y hora de la última transacción | |
| Campo de control | 20260817162604.0 |
| 007 - Tipo material - Descripcion fisica - info general | |
| Tipo material - Descripcion fisica - info general | ta |
| 008 - Elementos de Longitud Fija - Información General | |
| Elementos de Longitud Fija - Información | t pe ||||| |||| 00| 0 spa d |
| 040 ## - Origen de la Catalogación | |
| Origen de la Catalogación | BMG |
| 041 ## - Idioma | |
| Idioma | eng |
| 100 ## - Autor | |
| Autor | Mina, Roberto |
| Rol del Autor | Autor |
| 9 (RLIN) | 53814 |
| 245 ## - Titulo | |
| Titulo | Talquetamab–daratumumab in relapsed or refractory myeloma |
| 300 ## - Páginas | |
| Paginación | páginas: 671-683 |
| 520 ## - Resumen | |
| Resumen | Background: Talquetamab, a bispecific antibody targeting GPRC5D and CD3, has led to durable responses in patients with heavily pretreated relapsed or refractory multiple myeloma in phase 1–2 trials, with a limited effect on normal B cells. Methods: In a phase 3 trial, we randomly assigned patients with relapsed or refractory multiple myeloma who had previously received at least one line of therapy to receive talquetamab plus daratumumab and pomalidomide (Tal-DP), talquetamab plus daratumumab (Tal-D), or daratumumab plus pomalidomide and dexamethasone (DPd). The primary end point was progression-free survival as assessed by an independent review committee. Key secondary end points were overall response, complete response or better (complete or stringent complete response), measurable residual disease–negative complete response, and overall survival. Results: A total of 287, 287, and 290 patients were assigned to the Tal-DP, Tal-D, and DPd groups, respectively. At the interim analysis (median follow-up, 24.6 months), progression-free survival was significantly longer with Tal-DP and Tal-D than with DPd (24-month estimate, 81.3% and 77.6% vs. 51.2%; hazard ratio for disease progression or death, Tal-DP vs. DPd, 0.28 [95% confidence interval {CI}, 0.20 to 0.40], and Tal-D vs. DPd, 0.33 [95% CI, 0.24 to 0.46]; P<0.001 for both comparisons). The overall response was higher with Tal-DP and Tal-D than with DPd (88.2% and 88.5% vs. 77.6%), as was complete response or better (71.1% and 69.0% vs. 34.5%) and measurable residual disease–negative complete response (52.3% and 46.3% vs. 15.9%) (P<0.001 for all comparisons). Overall survival at 24 months was 89.2% with Tal-DP, 87.9% with Tal-D, and 79.1% with DPd (hazard ratio for death, Tal-DP vs. DPd, 0.47 [95% CI, 0.30 to 0.73], and Tal-D vs. DPd, 0.51 [95% CI, 0.33 to 0.78]). Serious adverse events occurred in 63.0%, 52.6%, and 53.7% of the patients in the Tal-DP, Tal-D, and DPd groups, respectively; fatal adverse events occurred in 1.8%, 4.0%, and 4.6%. Conclusions: Among patients with relapsed or refractory multiple myeloma who had previously received at least one line of therapy, both Tal-DP and Tal-D led to significantly longer progression-free survival than DPd. |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | LEUCEMIA |
| 9 (RLIN) | 33873 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | LINFOMA |
| 9 (RLIN) | 39360 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | CUIDADOS INTENSIVOS GENERAL |
| 9 (RLIN) | 54115 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | TRATAMIENTOS EN ONCOLOGÍA |
| 9 (RLIN) | 53734 |
| 700 ## - Autor Personal | |
| Autor Personal | Beksac, Meral |
| 9 (RLIN) | 54122 |
| 700 ## - Autor Personal | |
| Autor Personal | Rodríguez-Otero, Paula |
| 9 (RLIN) | 54123 |
| 700 ## - Autor Personal | |
| Autor Personal | Chen,Wenming |
| 9 (RLIN) | 53818 |
| 700 ## - Autor Personal | |
| Autor Personal | Mateos, María-Victoria |
| 9 (RLIN) | 54124 |
| 700 ## - Autor Personal | |
| Autor Personal | Li, Jian |
| 9 (RLIN) | 54125 |
| 700 ## - Autor Personal | |
| Autor Personal | Moreau, Philippe |
| 9 (RLIN) | 54126 |
| 700 ## - Autor Personal | |
| Autor Personal | Cohen, Yael C. |
| 9 (RLIN) | 54127 |
| 700 ## - Autor Personal | |
| Autor Personal | Min, Chang-Ki |
| 9 (RLIN) | 54128 |
| 773 0# - Revista (Relacion con el numero) | |
| Host Biblionumber | 22717 |
| Host Itemnumber | 22647 |
| Ciudad, Editorial | Massachusetts NEJM Group |
| Codigo barras item/ejemplar | NEJM010 |
| Titulo de la Revista | The New England Journal of Medicine |
| Número de control de registro | ESSALUD |
| ISSN | 0028-4793 |
| 942 ## - Elementos de Koha | |
| Tipo de Documento | Artículos |
| Fecha procesamiento | 2026-08-17 |
| Catalogador | SQB |
No hay ítems disponibles.